{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:39Z","timestamp":1787988039349,"version":"build-2784847793"},"reference-count":119,"publisher":"Walter de Gruyter GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neurodegenerative diseases, including Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), are multifactorial diseases that are characterized by several interconnected pathological mechanisms, such as the aggregation of amyloid-beta (A\u03b2), hyperphosphorylation of tau, accumulation of \u03b1-synuclein, oxidative stress, mitochondrial dysfunction, neuroinflammation, and neurotransmitter imbalance. Conventional single-target therapies failed to produce significant clinical effects due to the fact that they target only individual disease pathways. Thus, the multitarget-directed ligand (MTDL) strategy has become an attractive therapeutic option, and MTDLs can act on several pathological targets simultaneously. Recent advances in multitarget drug development for AD and PD targeting compounds targeting A\u03b2, BACE1, MAO-B, cholinesterases, metal-ion dyshomeostasis, oxidative stress, and inflammatory pathways are reviewed. A few potential candidates, such as GV-971, Prasinezumab, Huperzine A, curcumin derivatives, and hybrids of MAO-B inhibitors, have shown neuroprotective and cognitive effects in preclinical and clinical studies. There are significant advances in the clinical pipeline, with over 180 clinical trials for AD and over 130 clinical trials for PD testing multitarget or disease-modifying strategies. The review also highlights the growing importance of computer-aided drug design (CADD), artificial intelligence (AI), and machine learning (ML) in speeding up the discovery of MTDL, optimizing their pharmacokinetic profiles, and predicting multitarget interactions. However, there are still major obstacles to be overcome, such as the ability to cross the blood\u2013brain barrier, optimizing the pharmacokinetics, the difficulties of transferring from the animal to the human model, and the complexity of the regulatory process. New strategies based on nanomedicine, biomarker-driven trials, personalized medicine, and drug repurposing will enhance therapeutic precision and clinical success.<\/jats:p>","DOI":"10.1515\/znc-2026-0116","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:55:42Z","timestamp":1787986542000},"source":"Crossref","is-referenced-by-count":0,"title":["Multitargeted drug strategies for Alzheimer\u2019s and Parkinson\u2019s diseases"],"prefix":"10.1515","author":[{"given":"Azmat Ullah","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Chemistry , Quaid-i-Azam University Islamabad , 45320 , Islamabad , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Department of Chemistry , Quaid-i-Azam University Islamabad , 45320 , Islamabad , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Farwa","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Department of Zoology , Quaid-i-Azam University Islamabad , 45320 , Islamabad , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadia","family":"Tahir","sequence":"additional","affiliation":[{"name":"Department of Chemistry , Quaid-i-Azam University Islamabad , 45320 , Islamabad , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Chemistry , Quaid-i-Azam University Islamabad , 45320 , Islamabad , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Sarfraz","sequence":"additional","affiliation":[{"name":"Department of Chemistry , Quaid-i-Azam University Islamabad , 45320 , Islamabad , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-7849","authenticated-orcid":false,"given":"Yousaf","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Chemistry , COMSATS University Islamabad , 45550 , Islamabad , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026082906553315920_j_znc-2026-0116_ref_001","doi-asserted-by":"crossref","unstructured":"Bloem, BR, Okun, MS, Klein, C. Parkinson\u2019s disease. Lancet 2021;397:2284\u2013303.","DOI":"10.1016\/S0140-6736(21)00218-X"},{"key":"2026082906553315920_j_znc-2026-0116_ref_002","doi-asserted-by":"crossref","unstructured":"Pathak, N, Vimal, SK, Tandon, I, Agrawal, L, Hongyi, C, Bhattacharyya, S. Neurodegenerative disorders of Alzheimer, parkinsonism, amyotrophic lateral sclerosis and multiple sclerosis: an early diagnostic approach for precision treatment. Metab Brain Dis 2022;37:67\u2013104.","DOI":"10.1007\/s11011-021-00800-w"},{"key":"2026082906553315920_j_znc-2026-0116_ref_003","doi-asserted-by":"crossref","unstructured":"Elkin, I, Shea, MT, Watkins, JT, Imber, SD, Sotsky, SM, Collins, JF, et al.. National Institute of Mental Health treatment of depression collaborative research program: general effectiveness of treatments. Arch Gen Psychiatry 1989;46:971\u201382. https:\/\/doi.org\/10.1001\/archpsyc.1989.01810110013002.","DOI":"10.1001\/archpsyc.1989.01810110013002"},{"key":"2026082906553315920_j_znc-2026-0116_ref_004","doi-asserted-by":"crossref","unstructured":"Luo, H, Xiang, Y, Qu, X, Liu, H, Liu, C, Li, G, et al.. Apelin-13 suppresses neuroinflammation against cognitive deficit in a streptozotocin-induced rat model of Alzheimer\u2019s disease through activation of BDNF-TrkB signaling pathway. Front Pharmacol 2019;10:395. https:\/\/doi.org\/10.3389\/fphar.2019.00395.","DOI":"10.3389\/fphar.2019.00395"},{"key":"2026082906553315920_j_znc-2026-0116_ref_005","doi-asserted-by":"crossref","unstructured":"Tang, L, Liu, L, Li, G, Jiang, P, Wang, Y, Li, J. Expression profiles of long noncoding RNAs in intranasal LPS\u2010mediated Alzheimer\u2019s disease model in mice. BioMed Res Int 2019;2019:9642589. https:\/\/doi.org\/10.1155\/2019\/9642589.","DOI":"10.1155\/2019\/9642589"},{"key":"2026082906553315920_j_znc-2026-0116_ref_006","doi-asserted-by":"crossref","unstructured":"Zhao, Y, Zhao, B. Oxidative stress and the pathogenesis of Alzheimer\u2019 s disease. Oxid Med Cell Longev 2013;2013:316523. https:\/\/doi.org\/10.1155\/2013\/316523.","DOI":"10.1155\/2013\/316523"},{"key":"2026082906553315920_j_znc-2026-0116_ref_007","doi-asserted-by":"crossref","unstructured":"Zheng, H, Fridkin, M, Youdim, M. From single target to multitarget\/network therapeutics in Alzheimer\u2019s therapy. Pharmaceuticals 2014;7:113\u201335. https:\/\/doi.org\/10.3390\/ph7020113.","DOI":"10.3390\/ph7020113"},{"key":"2026082906553315920_j_znc-2026-0116_ref_008","doi-asserted-by":"crossref","unstructured":"Hossain, MS, Hussain, MH. Multi\u2010target drug design in Alzheimer\u2019s disease treatment: emerging technologies, advantages, challenges, and limitations. Pharmacol Res Perspect 2025;13:e70131.","DOI":"10.1002\/prp2.70131"},{"key":"2026082906553315920_j_znc-2026-0116_ref_009","doi-asserted-by":"crossref","unstructured":"Makhoba, XH, Viegas, C, Mosa, RA, Viegas, FPD, Pooe, OJ. Potential impact of the multi-target drug approach in the treatment of some complex diseases. Drug Des Dev Ther 2020:3235\u201349. https:\/\/doi.org\/10.2147\/DDDT.S257494.","DOI":"10.2147\/DDDT.S257494"},{"key":"2026082906553315920_j_znc-2026-0116_ref_010","doi-asserted-by":"crossref","unstructured":"Yan, Q, Qin, Q, Zhang, S, Chen, F, Ru, Y, Zhong, Y, et al.. Glial cell nutrient sensing: mechanisms of nutrients regulating Alzheimer\u2019s pathogenesis and precision intervention. Crit Rev Food Sci Nutr 2026;66:2335\u201351.","DOI":"10.1080\/10408398.2025.2568606"},{"key":"2026082906553315920_j_znc-2026-0116_ref_011","doi-asserted-by":"crossref","unstructured":"Almaghrabi, M. Multitarget-directed ligands for Alzheimer\u2019s disease: recent novel MTDLs and mechanistic insights. Pharmaceuticals 2025;18:1685.","DOI":"10.3390\/ph18111685"},{"key":"2026082906553315920_j_znc-2026-0116_ref_012","doi-asserted-by":"crossref","unstructured":"Alkhalifa, AE, Alkhalifa, O, Durdanovic, I, Ibrahim, DR, Maragkou, S. Oxidative stress and mitochondrial dysfunction in Alzheimer\u2019s disease: insights into pathophysiology and treatment. Am J Alzheimer\u2019s Dis Other Dementias 2025;2:17.","DOI":"10.3390\/jdad2020017"},{"key":"2026082906553315920_j_znc-2026-0116_ref_013","doi-asserted-by":"crossref","unstructured":"Torchilin, VP. Drug targeting. Eur J Pharmaceut Sci 2000;11:S81\u201391.","DOI":"10.1016\/S0928-0987(00)00166-4"},{"key":"2026082906553315920_j_znc-2026-0116_ref_014","doi-asserted-by":"crossref","unstructured":"Cacabelos, R, Mart\u00ednez-Iglesias, O, Cacabelos, N, Carrera, I, Corzo, L, Naidoo, V, et al.. Therapeutic options in Alzheimer\u2019s disease: from classic acetylcholinesterase inhibitors to multi-target drugs with pleiotropic activity. Life 2024;14:1555.","DOI":"10.3390\/life14121555"},{"key":"2026082906553315920_j_znc-2026-0116_ref_015","doi-asserted-by":"crossref","unstructured":"Katsoulaki, E-E, Dimopoulos, D, Hadjipavlou-Litina, D. Multitarget compounds designed for Alzheimer, Parkinson, and Huntington neurodegeneration diseases. Pharmaceuticals 2025;18:831.","DOI":"10.3390\/ph18060831"},{"key":"2026082906553315920_j_znc-2026-0116_ref_016","doi-asserted-by":"crossref","unstructured":"Zhang, J, Zhang, Y, Wang, J, Xia, Y, Zhang, J, Chen, L. Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Targeted Ther 2024;9:211.","DOI":"10.1038\/s41392-024-01911-3"},{"key":"2026082906553315920_j_znc-2026-0116_ref_017","unstructured":"Markiewicz, PJ, Thompson, G, Wardlaw, JM, Wimberley, C, Ritchie, C, Taylor, JP, et al.. The dementias platform UK PET\/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network. Eur J Nucl Med Mol Imag 2026;1\u201320."},{"key":"2026082906553315920_j_znc-2026-0116_ref_018","doi-asserted-by":"crossref","unstructured":"Grimwade, IJ, Enticknap, G, De Pablo Fernandez, E, Croft, CL. \u03b1-Synuclein in lewy body diseases: progress, remaining challenges and future perspectives. Expert Rev Mol Med 2026;1\u201344.","DOI":"10.1017\/erm.2026.10037"},{"key":"2026082906553315920_j_znc-2026-0116_ref_019","doi-asserted-by":"crossref","unstructured":"Sisodia, SS, Price, DL. Role of the \u03b2\u2010amyloid protein in Alzheimer\u2019s disease. FASEB J 1995;9:366\u201370. https:\/\/doi.org\/10.1096\/fasebj.9.5.7896005.","DOI":"10.1096\/fasebj.9.5.7896005"},{"key":"2026082906553315920_j_znc-2026-0116_ref_020","doi-asserted-by":"crossref","unstructured":"Francis, PT. Glutamatergic systems in Alzheimer\u2019s disease. Int J Geriatr Psychiatr 2003;18:S15\u201321. https:\/\/doi.org\/10.1002\/gps.934.","DOI":"10.1002\/gps.934"},{"key":"2026082906553315920_j_znc-2026-0116_ref_021","doi-asserted-by":"crossref","unstructured":"Butterfield, DA, Boyd-Kimball, D. Oxidative stress, amyloid-\u03b2 peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer\u2019s disease. J\u00a0Alzheimers Dis 2018;62:1345\u201367.","DOI":"10.3233\/JAD-170543"},{"key":"2026082906553315920_j_znc-2026-0116_ref_022","doi-asserted-by":"crossref","unstructured":"Jenner, P, Olanow, CW. Understanding cell death in Parkinson\u2019s disease. Ann Neurol 1998;44:S72\u201384. https:\/\/doi.org\/10.1002\/ana.410440712.","DOI":"10.1002\/ana.410440712"},{"key":"2026082906553315920_j_znc-2026-0116_ref_023","doi-asserted-by":"crossref","unstructured":"Damier, P, Hirsch, EC, Agid, Y, Graybiel, AM. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson\u2019s disease. Brain 1999;122:1437\u201348. https:\/\/doi.org\/10.1093\/brain\/122.8.1437.","DOI":"10.1093\/brain\/122.8.1437"},{"key":"2026082906553315920_j_znc-2026-0116_ref_024","doi-asserted-by":"crossref","unstructured":"Benskey, MJ, Perez, RG, Manfredsson, FP. The contribution of alpha synuclein to neuronal survival and function\u2013implications for Parkinson\u2019s disease. J\u00a0Neurochem 2016;137:331\u201359. https:\/\/doi.org\/10.1111\/jnc.13570.","DOI":"10.1111\/jnc.13570"},{"key":"2026082906553315920_j_znc-2026-0116_ref_025","doi-asserted-by":"crossref","unstructured":"Cramb, KM, Beccano-Kelly, D, Cragg, SJ, Wade-Martins, R. Impaired dopamine release in Parkinson\u2019s disease. Brain 2023;146:3117\u201332.","DOI":"10.1093\/brain\/awad064"},{"key":"2026082906553315920_j_znc-2026-0116_ref_026","doi-asserted-by":"crossref","unstructured":"Von Bartheld, CS, Bahney, J, Herculano\u2010Houzel, S. The search for true numbers of neurons and glial cells in the human brain: a review of 150\u00a0years of cell counting. J\u00a0Comp Neurol 2016;524:3865\u201395. https:\/\/doi.org\/10.1002\/cne.24040.","DOI":"10.1002\/cne.24040"},{"key":"2026082906553315920_j_znc-2026-0116_ref_027","doi-asserted-by":"crossref","unstructured":"Isik, S, Kiyak, BY, Akbayir, R, Seyhali, R, Arpaci, T. Microglia mediated neuroinflammation in Parkinson\u2019s disease. Cells 2023;12:1012.","DOI":"10.3390\/cells12071012"},{"key":"2026082906553315920_j_znc-2026-0116_ref_028","doi-asserted-by":"crossref","unstructured":"MacMahon Copas, AN, McComish, SF, Fletcher, JM, Caldwell, MA. The pathogenesis of Parkinson\u2019s disease: a complex interplay between astrocytes, microglia, and T lymphocytes? Front Neurol 2021;12:666737.","DOI":"10.3389\/fneur.2021.666737"},{"key":"2026082906553315920_j_znc-2026-0116_ref_029","doi-asserted-by":"crossref","unstructured":"Van Eldik, LJ, Thompson, WL, Ralay Ranaivo, H, Behanna, HA, Martin Watterson, D. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function\u2010based and target\u2010based discovery approaches. Int Rev Neurobiol 2007;82:277\u201396. https:\/\/doi.org\/10.1016\/S0074-7742(07)82015-0.","DOI":"10.1016\/S0074-7742(07)82015-0"},{"key":"2026082906553315920_j_znc-2026-0116_ref_030","doi-asserted-by":"crossref","unstructured":"Wang, Y, Wang, H, Chen, H-Z. AChE inhibition-based multi-target-directed ligands, a novel pharmacological approach for the symptomatic and disease-modifying therapy of Alzheimer\u2019s disease. Curr Neuropharmacol 2016;14:364\u201375. https:\/\/doi.org\/10.2174\/1570159x14666160119094820.","DOI":"10.2174\/1570159X14666160119094820"},{"key":"2026082906553315920_j_znc-2026-0116_ref_031","doi-asserted-by":"crossref","unstructured":"Buccheri, R, Rescifina, A. High-throughput, high-quality: benchmarking GNINA and AutoDock VINA for precision virtual screening workflow. Molecules 2025;30:3361.","DOI":"10.3390\/molecules30163361"},{"key":"2026082906553315920_j_znc-2026-0116_ref_032","doi-asserted-by":"crossref","unstructured":"Altharawi, A, Alqahtani, SM. Integrative computational chemistry approaches in modern drug discovery: advances in docking, pharmacophore modeling, molecular dynamics, and virtual screening. Pharmaceutics 2026;18:565.","DOI":"10.3390\/pharmaceutics18050565"},{"key":"2026082906553315920_j_znc-2026-0116_ref_033","doi-asserted-by":"crossref","unstructured":"Moriwaki, H, Kawashima, Y, Watanabe, C, Kamisaka, K, Okiyama, Y, Fukuzawa, K, et al.. FMOe: preprocessing and visualizing package of the fragment molecular orbital method for molecular operating environment and its applications in covalent ligand and metalloprotein analyses. J\u00a0Chem Inf Model 2024;64:6927\u201337.","DOI":"10.1021\/acs.jcim.4c01169"},{"key":"2026082906553315920_j_znc-2026-0116_ref_034","doi-asserted-by":"crossref","unstructured":"Redkar, AS, Ramakrishnan, V. Molecular dynamics simulations. In: . Biophysical characterization of functional peptides. Springer; 2023:17\u201322 pp.","DOI":"10.1007\/978-1-0716-3405-9_3"},{"key":"2026082906553315920_j_znc-2026-0116_ref_035","doi-asserted-by":"crossref","unstructured":"Correia, J, Capela, J, Rocha, M. Deepmol: an automated machine and deep learning framework for computational chemistry. J\u00a0Cheminf 2024;16:136.","DOI":"10.1186\/s13321-024-00937-7"},{"key":"2026082906553315920_j_znc-2026-0116_ref_036","doi-asserted-by":"crossref","unstructured":"Brown, ED, Wright, GD. New targets and screening approaches in antimicrobial drug discovery. Chem Rev 2005;105:759\u201374. https:\/\/doi.org\/10.1021\/cr030116o.","DOI":"10.1021\/cr030116o"},{"key":"2026082906553315920_j_znc-2026-0116_ref_037","doi-asserted-by":"crossref","unstructured":"Chandrasekaran, B, Abed, SN, Al-Attraqchi, O, Kuche, K, Tekade, R. Computer-aided prediction of pharmacokinetic (ADMET) properties. In: Dosage form design parameters. Amsterdam: Elsevier; 2018:731\u201355 pp.","DOI":"10.1016\/B978-0-12-814421-3.00021-X"},{"key":"2026082906553315920_j_znc-2026-0116_ref_038","doi-asserted-by":"crossref","unstructured":"Alber, M, Buganza Tepole, A, Cannon, WR, De, S, Dura-Bernal, S, Garikipati, K, et al.. Integrating machine learning and multiscale modeling\u2014perspectives, challenges, and opportunities in the biological, biomedical, and behavioral sciences. npj Digit Med 2019;2:115. https:\/\/doi.org\/10.1038\/s41746-019-0193-y.","DOI":"10.1038\/s41746-019-0193-y"},{"key":"2026082906553315920_j_znc-2026-0116_ref_039","doi-asserted-by":"crossref","unstructured":"Gupta, R, Srivastava, D, Sahu, M, Tiwari, S, Ambasta, R, Kumar, P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers 2021;25:1315\u201360.","DOI":"10.1007\/s11030-021-10217-3"},{"key":"2026082906553315920_j_znc-2026-0116_ref_040","doi-asserted-by":"crossref","unstructured":"Khalighi, S, Reddy, S, Midya, K, Pandav, KB, Madabhushi, A, Abedalthagafi, M. Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment. npj Precis Oncol 2024;8:80.","DOI":"10.1038\/s41698-024-00575-0"},{"key":"2026082906553315920_j_znc-2026-0116_ref_041","doi-asserted-by":"crossref","unstructured":"Momin, Y, Beloshe, V. Pharmacophore modeling in drug design. In: Advances in pharmacology. Elsevier; 2025:313\u201324 pp.","DOI":"10.1016\/bs.apha.2025.01.010"},{"key":"2026082906553315920_j_znc-2026-0116_ref_042","unstructured":"Ismail, AME-F. Detection and classification of skin cancer using deep convolutional neural networks (CNN) via KNIME analytics platform software. Surman J Food Sci Technol 2024;6:054\u201386."},{"key":"2026082906553315920_j_znc-2026-0116_ref_043","doi-asserted-by":"crossref","unstructured":"Cavalli, A, Bolognesi, ML, Minarini, A, Rosini, M, Tumiatti, V, Recanatini, M, et al.. Multi-target-directed ligands to combat neurodegenerative diseases. J\u00a0Med Chem 2008;51:347\u201372. https:\/\/doi.org\/10.1021\/jm7009364.","DOI":"10.1021\/jm7009364"},{"key":"2026082906553315920_j_znc-2026-0116_ref_044","unstructured":"Mannhold, R, Kubinyi, H, Folkers, G. Pharmacokinetics and metabolism in drug design. John Wiley & Sons; 2012."},{"key":"2026082906553315920_j_znc-2026-0116_ref_045","doi-asserted-by":"crossref","unstructured":"Zhou, J, Jiang, X, He, S, Jiang, H, Feng, F, Liu, W, et al.. Rational design of multitarget-directed ligands: strategies and emerging paradigms. J\u00a0Med Chem 2019;62:8881\u2013914.","DOI":"10.1021\/acs.jmedchem.9b00017"},{"key":"2026082906553315920_j_znc-2026-0116_ref_046","doi-asserted-by":"crossref","unstructured":"Niazi, SK, Mariam, Z. Computer-aided drug design and drug discovery: a prospective analysis. Pharmaceuticals 2023;17:22.","DOI":"10.3390\/ph17010022"},{"key":"2026082906553315920_j_znc-2026-0116_ref_047","doi-asserted-by":"crossref","unstructured":"Nesi, G, Sestito, S, Digiacomo, M, Rapposelli, S. Oxidative stress, mitochondrial abnormalities and proteins deposition: multitarget approaches in Alzheimer\u2019s disease. Curr Top Med Chem 2017;17:3062\u201379. https:\/\/doi.org\/10.2174\/1568026617666170607114232.","DOI":"10.2174\/1568026617666170607114232"},{"key":"2026082906553315920_j_znc-2026-0116_ref_048","doi-asserted-by":"crossref","unstructured":"Simunkova, M, Alwasel, SH, Alhazza, IM, Jomova, K, Kollar, V, Rusko, M, et al.. Management of oxidative stress and other pathologies in Alzheimer\u2019s disease. Arch Toxicol 2019;93:2491\u2013513. https:\/\/doi.org\/10.1007\/s00204-019-02538-y.","DOI":"10.1007\/s00204-019-02538-y"},{"key":"2026082906553315920_j_znc-2026-0116_ref_049","doi-asserted-by":"crossref","unstructured":"Du, Z, Li, M, Ren, J, Qu, X. Current strategies for modulating A\u03b2 aggregation with multifunctional agents. Acc Chem Res 2021;54:2172\u201384.","DOI":"10.1021\/acs.accounts.1c00055"},{"key":"2026082906553315920_j_znc-2026-0116_ref_050","doi-asserted-by":"crossref","unstructured":"Bhatt, S, Puli, L, Patil, CR. Role of reactive oxygen species in the progression of Alzheimer\u2019s disease. Drug Discov Today 2021;26:794\u2013803.","DOI":"10.1016\/j.drudis.2020.12.004"},{"key":"2026082906553315920_j_znc-2026-0116_ref_051","doi-asserted-by":"crossref","unstructured":"Unzeta, M, Esteban, G, Bolea, I, Fogel, WA, Ramsay, RR, Youdim, MB, et al.. Multi-target directed donepezil-like ligands for Alzheimer\u2019s disease. Front Neurosci 2016;10:205.","DOI":"10.3389\/fnins.2016.00205"},{"key":"2026082906553315920_j_znc-2026-0116_ref_052","doi-asserted-by":"crossref","unstructured":"Behl, T, Kaur, D, Sehgal, A, Singh, S, Sharma, N, Zengin, G, et al.. Role of monoamine oxidase activity in Alzheimer\u2019s disease: an insight into the therapeutic potential of inhibitors. Molecules 2021;26:3724.","DOI":"10.3390\/molecules26123724"},{"key":"2026082906553315920_j_znc-2026-0116_ref_053","doi-asserted-by":"crossref","unstructured":"Obaid, RJ, Naeem, N, Mughal, EU, Al-Rooqi, MM, Sadiq, A, Jassas, RS, et al.. Inhibitory potential of nitrogen, oxygen and sulfur containing heterocyclic scaffolds against acetylcholinesterase and butyrylcholinesterase. RSC Adv 2022;12:19764\u2013855.","DOI":"10.1039\/D2RA03081K"},{"key":"2026082906553315920_j_znc-2026-0116_ref_054","doi-asserted-by":"crossref","unstructured":"Yoo, J, Lee, J, Ahn, B, Han, J, Lim, MH. Multi-target-directed therapeutic strategies for Alzheimer\u2019s disease: controlling amyloid-\u03b2 aggregation, metal ion homeostasis, and enzyme inhibition. Chem Sci 2025;16:2105\u201335.","DOI":"10.1039\/D4SC06762B"},{"key":"2026082906553315920_j_znc-2026-0116_ref_055","doi-asserted-by":"crossref","unstructured":"Shevtsova, EF, Aksinenko, AY, Stavrovskaya, AV, Fisenko, VP, Bachurin, SO. Mitochondrial and antioxidant activity as the basis of the neuroprotective effect of potential multitarget drugs for the treatment of neurodegenerative diseases. Curr Neuropharmacol 2026. https:\/\/doi.org\/10.2174\/011570159X409525251027064739.","DOI":"10.2174\/011570159X409525251027064739"},{"key":"2026082906553315920_j_znc-2026-0116_ref_056","unstructured":"Tavartkiladze, A, Reiter, RJ. Melatonin and human mitochondria: physiology, pathochemistry, and immunogenetics. Receptor;1:6."},{"key":"2026082906553315920_j_znc-2026-0116_ref_057","doi-asserted-by":"crossref","unstructured":"Pluta, R, Furmaga-Jab\u0142o\u0144ska, W, Januszewski, S, Czuczwar, SJ. Post-ischemic brain neurodegeneration in the form of Alzheimer\u2019s disease proteinopathy: possible therapeutic role of curcumin. Nutrients 2022;14:248.","DOI":"10.3390\/nu14020248"},{"key":"2026082906553315920_j_znc-2026-0116_ref_058","doi-asserted-by":"crossref","unstructured":"Silva, P, Rodr\u00edguez-P\u00e9rez, M, G\u00f3mez-Torres, \u00d3, Burgos-Ramos, E. Olive oil and wine as source of multi-target agents in the prevention of Alzheimer disease. Nutr Res Rev 2023;36:140\u201354.","DOI":"10.1017\/S095442242100041X"},{"key":"2026082906553315920_j_znc-2026-0116_ref_059","doi-asserted-by":"crossref","unstructured":"Durrenberger, PF, Fernando, FS, Kashefi, SN, Bonnert, TP, Seilhean, D, Nait-Oumesmar, B, et al.. Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. J\u00a0Neural Transm 2015;122:1055\u201368. https:\/\/doi.org\/10.1007\/s00702-014-1293-0.","DOI":"10.1007\/s00702-014-1293-0"},{"key":"2026082906553315920_j_znc-2026-0116_ref_060","doi-asserted-by":"crossref","unstructured":"Fernie, AR, Carrari, F, Sweetlove, LJ. Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr Opin Plant Biol 2004;7:254\u201361. https:\/\/doi.org\/10.1016\/j.pbi.2004.03.007.","DOI":"10.1016\/j.pbi.2004.03.007"},{"key":"2026082906553315920_j_znc-2026-0116_ref_061","doi-asserted-by":"crossref","unstructured":"Preti, D, Baraldi, PG, Moorman, AR, Borea, PA, Varani, K. History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents. Med Res Rev 2015;35:790\u2013848. https:\/\/doi.org\/10.1002\/med.21344.","DOI":"10.1002\/med.21344"},{"key":"2026082906553315920_j_znc-2026-0116_ref_062","unstructured":"Mills, SE. Sternberg\u2019s diagnostic surgical pathology. Lippincott Williams & Wilkins; 2012."},{"key":"2026082906553315920_j_znc-2026-0116_ref_063","doi-asserted-by":"crossref","unstructured":"Li, M, Jancovski, N, Jafar-Nejad, P, Burbano, LE, Rollo, B, Richards, K, et al.. Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model. J\u00a0Clin Investig 2021;131.","DOI":"10.1172\/JCI152079"},{"key":"2026082906553315920_j_znc-2026-0116_ref_064","doi-asserted-by":"crossref","unstructured":"Califf, RM. Biomarker definitions and their applications. Exp Biol Med 2018;243:213\u201321. https:\/\/doi.org\/10.1177\/1535370217750088.","DOI":"10.1177\/1535370217750088"},{"key":"2026082906553315920_j_znc-2026-0116_ref_065","doi-asserted-by":"crossref","unstructured":"Wang, R, Yan, H, Tang, XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine 1. Acta Pharmacol Sin 2006;27:1\u201326. https:\/\/doi.org\/10.1111\/j.1745-7254.2006.00255.x.","DOI":"10.1111\/j.1745-7254.2006.00255.x"},{"key":"2026082906553315920_j_znc-2026-0116_ref_066","doi-asserted-by":"crossref","unstructured":"Tombros, A, Sanderson, M. Advantages of query biased summaries in information retrieval.; 1998.Proceedings of the 21st annual international ACM SIGIR conference on Research and development in information retrieval.","DOI":"10.1145\/290941.290947"},{"key":"2026082906553315920_j_znc-2026-0116_ref_067","doi-asserted-by":"crossref","unstructured":"Wang, HJ, Chinna-Meyyappan, A, Feldman, OJ, Lanct\u00f4t, KL. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer\u2019s disease. Expert Opin Emerg Drugs 2024;29:289\u2013303.","DOI":"10.1080\/14728214.2024.2363215"},{"key":"2026082906553315920_j_znc-2026-0116_ref_068","doi-asserted-by":"crossref","unstructured":"Cardoso, S, Carvalho, C, Correia, SC, Sei\u00e7a, RM, Moreira, PI. Alzheimer\u2019s disease: from mitochondrial perturbations to mitochondrial medicine. Brain Pathol 2016;26:632\u201347.","DOI":"10.1111\/bpa.12402"},{"key":"2026082906553315920_j_znc-2026-0116_ref_069","doi-asserted-by":"crossref","unstructured":"Gonzales, MM, Garbarino, VR, Kautz, TF, Palavicini, JP, Lopez-Cruzan, M, Dehkordi, SK, et al.. Senolytic therapy in mild Alzheimer\u2019s disease: a phase 1 feasibility trial. Nat Med 2023;29:2481\u20138.","DOI":"10.1038\/s41591-023-02543-w"},{"key":"2026082906553315920_j_znc-2026-0116_ref_070","doi-asserted-by":"crossref","unstructured":"Huang, L-K, Chao, S-P, Hu, C-J. Clinical trials of new drugs for Alzheimer disease. J\u00a0Biomed Sci 2020;27:18. https:\/\/doi.org\/10.1186\/s12929-019-0609-7.","DOI":"10.1186\/s12929-019-0609-7"},{"key":"2026082906553315920_j_znc-2026-0116_ref_071","doi-asserted-by":"crossref","unstructured":"Burge, R, Dawson-Hughes, B, Solomon, DH, Wong, JB, King, A, Tosteson, A. Incidence and economic burden of osteoporosis\u2010related fractures in the United\u00a0States, 2005\u20132025. J\u00a0Bone Miner Res 2007;22:465\u201375. https:\/\/doi.org\/10.1359\/jbmr.061113.","DOI":"10.1359\/jbmr.061113"},{"key":"2026082906553315920_j_znc-2026-0116_ref_072","doi-asserted-by":"crossref","unstructured":"Chasseigneaux, S, Allinquant, B. Functions of A\u03b2, sAPP\u03b1 and sAPP\u03b2: similarities and differences. J\u00a0Neurochem 2012;120:99\u2013108. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07584.x.","DOI":"10.1111\/j.1471-4159.2011.07584.x"},{"key":"2026082906553315920_j_znc-2026-0116_ref_073","doi-asserted-by":"crossref","unstructured":"Dzau, VJ, Antman, EM, Black, HR, Hayes, DL, Manson, JE, Plutzky, J, et al.. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006;114:2850\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.655688.","DOI":"10.1161\/CIRCULATIONAHA.106.655688"},{"key":"2026082906553315920_j_znc-2026-0116_ref_074","doi-asserted-by":"crossref","unstructured":"Maetzler, W, Liepelt, I, Berg, D. Progression of Parkinson\u2019s disease in the clinical phase: potential markers. Lancet Neurol 2009;8:1158\u201371. https:\/\/doi.org\/10.1016\/S1474-4422(09)70291-1.","DOI":"10.1016\/S1474-4422(09)70291-1"},{"key":"2026082906553315920_j_znc-2026-0116_ref_075","doi-asserted-by":"crossref","unstructured":"Loh, JS, Mak, WQ, Tan, LKS, Ng, CX, Chan, HH, Yeow, SH, et al.. Microbiota\u2013gut\u2013brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Targeted Ther 2024;9:37.","DOI":"10.1038\/s41392-024-01743-1"},{"key":"2026082906553315920_j_znc-2026-0116_ref_076","doi-asserted-by":"crossref","unstructured":"Kueper, JK, Speechley, M, Montero-Odasso, M. The Alzheimer\u2019s disease assessment scale\u2013cognitive subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. A narrative review. J\u00a0Alzheimers Dis 2018;63:423\u201344. https:\/\/doi.org\/10.3233\/JAD-170991.","DOI":"10.3233\/JAD-170991"},{"key":"2026082906553315920_j_znc-2026-0116_ref_077","doi-asserted-by":"crossref","unstructured":"Hara, Y, McKeehan, N, Dacks, PA, Fillit, HM. Evaluation of the neuroprotective potential of N-acetylcysteine for prevention and treatment of cognitive aging and dementia. J\u00a0Prev Alzheimers Dis 2017;10.","DOI":"10.14283\/jpad.2017.22"},{"key":"2026082906553315920_j_znc-2026-0116_ref_078","doi-asserted-by":"crossref","unstructured":"Shrivastava, P, Vaibhav, K, Tabassum, R, Khan, A, Ishrat, T, Khan, MM, et al.. Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson\u2019s rat model. J\u00a0Nutr Biochem 2013;24:680\u20137. https:\/\/doi.org\/10.1016\/j.jnutbio.2012.03.018.","DOI":"10.1016\/j.jnutbio.2012.03.018"},{"key":"2026082906553315920_j_znc-2026-0116_ref_079","doi-asserted-by":"crossref","unstructured":"Newman, DJ, Cragg, GM. Marine natural products and related compounds in clinical and advanced preclinical trials. J\u00a0Nat Prod 2004;67:1216\u201338. https:\/\/doi.org\/10.1021\/np040031y.","DOI":"10.1021\/np040031y"},{"key":"2026082906553315920_j_znc-2026-0116_ref_080","doi-asserted-by":"crossref","unstructured":"Hwang, TJ, Carpenter, D, Lauffenburger, JC, Wang, B, Franklin, JM, Kesselheim, AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 2016;176:1826\u201333. https:\/\/doi.org\/10.1001\/jamainternmed.2016.6008.","DOI":"10.1001\/jamainternmed.2016.6008"},{"key":"2026082906553315920_j_znc-2026-0116_ref_081","doi-asserted-by":"crossref","unstructured":"Vasan, RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.482570.","DOI":"10.1161\/CIRCULATIONAHA.104.482570"},{"key":"2026082906553315920_j_znc-2026-0116_ref_082","doi-asserted-by":"crossref","unstructured":"Cummings, J. Disease modification and neuroprotection in neurodegenerative disorders. Transl Neurodegener 2017;6:25. https:\/\/doi.org\/10.1186\/s40035-017-0096-2.","DOI":"10.1186\/s40035-017-0096-2"},{"key":"2026082906553315920_j_znc-2026-0116_ref_083","doi-asserted-by":"crossref","unstructured":"Pallmann, P, Bedding, AW, Choodari-Oskooei, B, Dimairo, M, Flight, L, Hampson, LV, et al.. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med 2018;16:29. https:\/\/doi.org\/10.1186\/s12916-018-1017-7.","DOI":"10.1186\/s12916-018-1017-7"},{"key":"2026082906553315920_j_znc-2026-0116_ref_084","doi-asserted-by":"crossref","unstructured":"Lang, AE, Espay, AJ. Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov Disord 2018;33:660\u201377. https:\/\/doi.org\/10.1002\/mds.27360.","DOI":"10.1002\/mds.27360"},{"key":"2026082906553315920_j_znc-2026-0116_ref_085","doi-asserted-by":"crossref","unstructured":"Piguet, F, Alves, S, Cartier, N. Clinical gene therapy for neurodegenerative diseases: past, present, and future. Hum Gene Ther 2017;28:988\u20131003. https:\/\/doi.org\/10.1089\/hum.2017.160.","DOI":"10.1089\/hum.2017.160"},{"key":"2026082906553315920_j_znc-2026-0116_ref_086","doi-asserted-by":"crossref","unstructured":"Prati, F, Bottegoni, G, Bolognesi, ML, Cavalli, A. BACE-1 inhibitors: from recent single-target molecules to multitarget compounds for Alzheimer\u2019s disease: miniperspective. J\u00a0Med Chem 2018;61:619\u201337. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00393.","DOI":"10.1021\/acs.jmedchem.7b00393"},{"key":"2026082906553315920_j_znc-2026-0116_ref_087","doi-asserted-by":"crossref","unstructured":"Hu, C, Dignam, JJ. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precis Oncol 2019:1:1\u201312.","DOI":"10.1200\/PO.19.00086"},{"key":"2026082906553315920_j_znc-2026-0116_ref_088","doi-asserted-by":"crossref","unstructured":"Abatematteo, FS, Niso, M, Contino, M, Leopoldo, M, Abate, C. Multi-target directed ligands (MTDLs) binding the \u03c31 receptor as promising therapeutics: state of the art and perspectives. Int J Mol Sci 2021;22:6359.","DOI":"10.3390\/ijms22126359"},{"key":"2026082906553315920_j_znc-2026-0116_ref_089","doi-asserted-by":"crossref","unstructured":"Selyutina, OY, Polyakov, NE, Korneev, DV, Zaitsev, BN. Influence of glycyrrhizin on permeability and elasticity of cell membrane: perspectives for drugs delivery. Drug Deliv 2016;23:848\u201355. https:\/\/doi.org\/10.3109\/10717544.2014.919544.","DOI":"10.3109\/10717544.2014.919544"},{"key":"2026082906553315920_j_znc-2026-0116_ref_090","doi-asserted-by":"crossref","unstructured":"Ramsay, RR, Popovic-Nikolic, MR, Nikolic, K, Uliassi, E, Bolognesi, ML. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med 2018;7:3. https:\/\/doi.org\/10.1186\/s40169-017-0181-2.","DOI":"10.1186\/s40169-017-0181-2"},{"key":"2026082906553315920_j_znc-2026-0116_ref_091","doi-asserted-by":"crossref","unstructured":"Alcaro, S, Bolognesi, ML, Garc\u00eda-Sosa, AT, Rapposelli, S. Multi-target-directed ligands (MTDL) as challenging research tools in drug discovery: from design to pharmacological evaluation. Frontiers Media SA; 2019:71 p.","DOI":"10.3389\/fchem.2019.00071"},{"key":"2026082906553315920_j_znc-2026-0116_ref_092","doi-asserted-by":"crossref","unstructured":"Oljacic, S, Popovic-Nikolic, M, Filipic, B, Gagic, Z, Nikolic, K. Computer-aided drug discovery of epigenetic modulators in dual-target therapy of multifactorial diseases. Curr Top Med Chem 2025;25:1907\u201339. https:\/\/doi.org\/10.2174\/0115680266337668241025061804.","DOI":"10.2174\/0115680266337668241025061804"},{"key":"2026082906553315920_j_znc-2026-0116_ref_093","doi-asserted-by":"crossref","unstructured":"Yuan, Y-H, Wang, CC, Duan, JL, Zhang, PP, He, ML, Liu, Z, et al.. Design, synthesis, and biological evaluation of aminopyrazine-based ATR\/HDACs dual inhibitors. Mol Divers 2026;30:1527\u201351.","DOI":"10.1007\/s11030-025-11282-8"},{"key":"2026082906553315920_j_znc-2026-0116_ref_094","doi-asserted-by":"crossref","unstructured":"Upadhyay, RK. Drug delivery systems, CNS protection, and the blood brain barrier. BioMed Res Int 2014;2014:869269. https:\/\/doi.org\/10.1155\/2014\/869269.","DOI":"10.1155\/2014\/869269"},{"key":"2026082906553315920_j_znc-2026-0116_ref_095","doi-asserted-by":"crossref","unstructured":"KrolI, RA, Neuwelt, EA, Neuwelt, EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083\u201399.","DOI":"10.1097\/00006123-199805000-00082"},{"key":"2026082906553315920_j_znc-2026-0116_ref_096","doi-asserted-by":"crossref","unstructured":"Zhou, X, Smith, QR, Liu, X. Brain penetrating peptides and peptide\u2013drug conjugates to overcome the blood\u2013brain barrier and target CNS diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1695.","DOI":"10.1002\/wnan.1695"},{"key":"2026082906553315920_j_znc-2026-0116_ref_097","doi-asserted-by":"crossref","unstructured":"Herv\u00e9, F, Ghinea, N, Scherrmann, J-M. CNS delivery via adsorptive transcytosis. AAPS J 2008;10:455\u201372. https:\/\/doi.org\/10.1208\/s12248-008-9055-2.","DOI":"10.1208\/s12248-008-9055-2"},{"key":"2026082906553315920_j_znc-2026-0116_ref_098","doi-asserted-by":"crossref","unstructured":"Torchilin, VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007;24:1\u201316. https:\/\/doi.org\/10.1007\/s11095-006-9132-0.","DOI":"10.1007\/s11095-006-9132-0"},{"key":"2026082906553315920_j_znc-2026-0116_ref_099","doi-asserted-by":"crossref","unstructured":"Rivera, VM. Multiple sclerosis: a global concern with multiple challenges in an era of advanced therapeutic complex molecules and biological medicines. Biomedicines 2018;6:112.","DOI":"10.3390\/biomedicines6040112"},{"key":"2026082906553315920_j_znc-2026-0116_ref_100","doi-asserted-by":"crossref","unstructured":"Marchetti, S, Schellens, J. The impact of FDA and EMEA guidelines on drug development in relation to phase 0 trials. Br J Cancer 2007;97:577\u201381. https:\/\/doi.org\/10.1038\/sj.bjc.6603925.","DOI":"10.1038\/sj.bjc.6603925"},{"key":"2026082906553315920_j_znc-2026-0116_ref_101","doi-asserted-by":"crossref","unstructured":"Darrow, JJ, Avorn, J, Kesselheim, AS. FDA approval and regulation of pharmaceuticals, 1983-2018. JAMA 2020;323:164\u201376. https:\/\/doi.org\/10.1001\/jama.2019.20288.","DOI":"10.1001\/jama.2019.20288"},{"key":"2026082906553315920_j_znc-2026-0116_ref_102","doi-asserted-by":"crossref","unstructured":"Gavel, H, Kumar, R, Azad, C. Challenges and future directions in applying machine learning to neurodegenerative disorders. In: Machine learning for neurodegenerative disorders. CRC Press:223\u201350 pp.","DOI":"10.1201\/9781032661025-11"},{"key":"2026082906553315920_j_znc-2026-0116_ref_103","doi-asserted-by":"crossref","unstructured":"Myszczynska, MA, Ojamies, PN, Lacoste, AMB, Neil, D, Saffari, A, Mead, R, et al.. Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. Nat Rev Neurol 2020;16:440\u201356. https:\/\/doi.org\/10.1038\/s41582-020-0377-8.","DOI":"10.1038\/s41582-020-0377-8"},{"key":"2026082906553315920_j_znc-2026-0116_ref_104","doi-asserted-by":"crossref","unstructured":"Saeidnia, S, Manayi, A, Abdollahi, M. From in\u00a0vitro experiments to in\u00a0vivo and clinical studies; pros and cons. Curr Drug Discov Technol 2015;12:218\u201324. https:\/\/doi.org\/10.2174\/1570163813666160114093140.","DOI":"10.2174\/1570163813666160114093140"},{"key":"2026082906553315920_j_znc-2026-0116_ref_105","doi-asserted-by":"crossref","unstructured":"McGonigle, P, Ruggeri, B. Animal models of human disease: challenges in enabling translation. Biochem Pharmacol 2014;87:162\u201371. https:\/\/doi.org\/10.1016\/j.bcp.2013.08.006.","DOI":"10.1016\/j.bcp.2013.08.006"},{"key":"2026082906553315920_j_znc-2026-0116_ref_106","doi-asserted-by":"crossref","unstructured":"Ahmad, A, Imran, M, Ahsan, H. Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics 2023;15:1630.","DOI":"10.3390\/pharmaceutics15061630"},{"key":"2026082906553315920_j_znc-2026-0116_ref_107","doi-asserted-by":"crossref","unstructured":"Alves, PA, Camargo, LC, Souza, Gmd, Mortari, MR, Homem-de-Mello, M. Computational modeling of pharmaceuticals with an emphasis on crossing the blood\u2013brain barrier. Pharmaceuticals 2025;18:217.","DOI":"10.3390\/ph18020217"},{"key":"2026082906553315920_j_znc-2026-0116_ref_108","doi-asserted-by":"crossref","unstructured":"Dehay, B, Bourdenx, M, Gorry, P, Przedborski, S, Vila, M, Hunot, S, et al.. Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol 2015;14:855\u201366. https:\/\/doi.org\/10.1016\/S1474-4422(15)00006-X.","DOI":"10.1016\/S1474-4422(15)00006-X"},{"key":"2026082906553315920_j_znc-2026-0116_ref_109","doi-asserted-by":"crossref","unstructured":"Matthews, H, Hanison, J, Nirmalan, N. Omics\u201d-informed drug and biomarker discovery: opportunities, challenges and future perspectives. Proteomes 2016;4:28. https:\/\/doi.org\/10.3390\/proteomes4030028.","DOI":"10.3390\/proteomes4030028"},{"key":"2026082906553315920_j_znc-2026-0116_ref_110","doi-asserted-by":"crossref","unstructured":"Fu, H, Hardy, J, Duff, KE. Selective vulnerability in neurodegenerative diseases. Nat Neurosci 2018;21:1350\u20138. https:\/\/doi.org\/10.1038\/s41593-018-0221-2.","DOI":"10.1038\/s41593-018-0221-2"},{"key":"2026082906553315920_j_znc-2026-0116_ref_111","doi-asserted-by":"crossref","unstructured":"Sun, W, Sanderson, PE, Zheng, W. Drug combination therapy increases successful drug repositioning. Drug Discov Today 2016;21:1189\u201395. https:\/\/doi.org\/10.1016\/j.drudis.2016.05.015.","DOI":"10.1016\/j.drudis.2016.05.015"},{"key":"2026082906553315920_j_znc-2026-0116_ref_112","doi-asserted-by":"crossref","unstructured":"Bolognesi, ML, Minarini, A, Rosini, M, Tumiatti, V, Melchiorre, C. From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer\u2019s disease. Mini Rev Med Chem 2008;8:960\u20137. https:\/\/doi.org\/10.2174\/138955708785740652.","DOI":"10.2174\/138955708785740652"},{"key":"2026082906553315920_j_znc-2026-0116_ref_113","doi-asserted-by":"crossref","unstructured":"Cha, Y, Erez, T, Reynolds, IJ, Kumar, D, Ross, J, Koytiger, G, et al.. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol 2018;175:168\u201380. https:\/\/doi.org\/10.1111\/bph.13798.","DOI":"10.1111\/bph.13798"},{"key":"2026082906553315920_j_znc-2026-0116_ref_114","doi-asserted-by":"crossref","unstructured":"Strianese, O, Rizzo, F, Ciccarelli, M, Galasso, G, D\u2019Agostino, Y, Salvati, A, et al.. Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes 2020;11:747. https:\/\/doi.org\/10.3390\/genes11070747.","DOI":"10.3390\/genes11070747"},{"key":"2026082906553315920_j_znc-2026-0116_ref_115","doi-asserted-by":"crossref","unstructured":"Subramanian, TS. Nanomedicine for neurodegenerative diseases. In: . Nanomedicine: Emerging Prospects. Springer; 2023:33\u201343 pp.","DOI":"10.1007\/978-981-99-2139-3_3"},{"key":"2026082906553315920_j_znc-2026-0116_ref_116","doi-asserted-by":"crossref","unstructured":"Chiaradia, I, Imaz-Rosshandler, I, Nilges, BS, Boulanger, J, Pellegrini, L, Das, R, et al.. Tissue morphology influences the temporal program of human brain organoid development. Cell Stem Cell 2023;30:1351\u201367.","DOI":"10.1016\/j.stem.2023.09.003"},{"key":"2026082906553315920_j_znc-2026-0116_ref_117","doi-asserted-by":"crossref","unstructured":"Boenink, M, van der Molen, L. The biomarkerization of Alzheimer\u2019s disease: from (early) diagnosis to anticipation? In: A Pragmatic approach to conceptualization of health and disease. Springer; 2024:141\u201362 pp.","DOI":"10.1007\/978-3-031-62241-0_11"},{"key":"2026082906553315920_j_znc-2026-0116_ref_118","doi-asserted-by":"crossref","unstructured":"Zi\u0119ba, A, St\u0119pnicki, P, Matosiuk, D, Kaczor, AA. What are the challenges with multi-targeted drug design for complex diseases? Expert Opin Drug Discov 2022;17:673\u201383.","DOI":"10.1080\/17460441.2022.2072827"},{"key":"2026082906553315920_j_znc-2026-0116_ref_119","doi-asserted-by":"crossref","unstructured":"Abanemea, D, Chemjong, K, Wiafe, E, Moshood, KO. AI-Driven drug discovery and translational medicine: from computational models to clinical impact. J\u00a0Adv Med Med Res 2026;38:161\u201376.","DOI":"10.9734\/jammr\/2026\/v38i46124"}],"container-title":["Zeitschrift f\u00fcr Naturforschung C"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/znc-2026-0116\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/znc-2026-0116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:55:54Z","timestamp":1787986554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/znc-2026-0116\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":119,"alternative-id":["10.1515\/znc-2026-0116"],"URL":"https:\/\/doi.org\/10.1515\/znc-2026-0116","relation":{},"ISSN":["0939-5075","1865-7125"],"issn-type":[{"value":"0939-5075","type":"print"},{"value":"1865-7125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}